Purpose: To evaluate the seropositivity of human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) and syphilis from blood samples of cornea donors and assess correlation between seropositivity for HIV and syphilis.
Methods: Retrospective analysis of blood samples of 31,355 cornea donors for HIV, HBV, HCV, and syphilis was performed. Postmortem blood samples were analyzed by a rapid screening test for anti-HIV envelope antibodies against HIV 1 and 2, HBV surface antigen, antibody to HCV and anti-cardiolipin antibodies for syphilis by rapid plasma reagin test.
Results: The overall seropositivity rate was 4.28% (1343/31,355 donors). All positive donors were reactive for a single serological test. The seropositivity rate for HIV was 0.93% (95% CI 0.83-1.04%), for HBsAg was 1.56% (95% CI 1.43-1.7%), for HCV was 1.19% (95% CI 1.08-1.33%) and for syphilis was 0.59% (95% CI 0.52-0.69%). The trends in seropositivity rates showed a decline for three viral markers: HIV (2010, 1.17% to 2018, 0.72%, p = 0.02), HBsAg (2010, 1.98% to 2018, 1.05%, p = 0.0006) and HCV (2010, 1.32% to 2018, 0.43%, p < 0.0001). The seropositivity rates for syphilis showed a progressive increase when compared to baseline (2010, 0.14% to 2018, 1.14%, p < 0.0001). There was no relationship between seropositivity for HIV and syphilis (p = 0.18).
Conclusions: The overall seropositivity for HIV, HBV, HCV and syphilis was 4.28%. Seropositivity was highest for HBV. The study did not find correlation between seropositivity of HIV and syphilis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10792-021-01733-0 | DOI Listing |
JCI Insight
January 2025
Medical Oncology Department, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, Netherlands.
Background: Previously, we demonstrated that changes in circulating tumor DNA (ctDNA) are promising biomarkers for early response prediction (ERP) to immune checkpoint inhibitors (ICI) in metastatic urothelial cancer (mUC). In this study, we investigated the value of whole blood immunotranscriptomics for ERP-ICI and integrated both biomarkers into a multimodal model to boost accuracy.
Methods: Blood samples of 93 patients were collected at baseline and after 2-6 weeks of ICI for ctDNA (N=88) and immunotranscriptome (N=79) analyses.
Infect Dis Ther
January 2025
Vaccine Research and Development, Pfizer R&D UK Ltd, Marlow, UK.
Introduction: Infants and young children typically have the highest age-related risk of invasive meningococcal disease. The immunogenicity and safety of a single primary dose and a booster of a meningococcal A/C/W/Y tetanus toxoid conjugate vaccine (MenACWY-TT; Nimenrix) in infants were evaluated.
Methods: In this phase 3b, open-label, single-arm study, healthy 3-month-old infants received a single Nimenrix dose followed by a booster at age 12 months (1 + 1 series).
Environ Sci Pollut Res Int
January 2025
Natural Resources Management and Development Team, Environment and Health Laboratory, Department of Biology, Faculty of Sciences, Moulay Ismaïl University, Zitoune, B.P.11201, Meknes, Morocco.
This study investigates the concentration of heavy metals lead (Pb), cadmium (Cd), and zinc (Zn) in the blood of house sparrows (Passer domesticus) across various urban habitats in Meknes, Morocco. Fifty adult sparrows were captured from five distinct sites, including industrial, high-traffic, and rural areas. Blood samples were specifically analyzed for Pb, Cd, and Zn using Inductively Coupled Plasma Atomic Emission Spectroscopy (ICP-AES).
View Article and Find Full Text PDFAdv Biotechnol (Singap)
June 2024
MOE Key Laboratory of Gene Function and Regulation, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-Sen University, Guangzhou, Guangdong, 510275, China.
Autosomal dominant polycystic kidney disease (ADPKD) is a dominant genetic disorder caused primarily by mutations in the PKD1 gene, resulting in the formation of numerous cysts and eventually kidney failure. However, there are currently no gene therapy studies aimed at correcting PKD1 gene mutations. In this study, we identified two mutation sites associated with ADPKD, c.
View Article and Find Full Text PDFJ Gastroenterol
January 2025
Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Mitaka, Japan.
Background: Despite the availability of several biologics for ulcerative colitis (UC), there remains a critical need to identify first-line treatment biologics. The superiority of infliximab (IFX) over vedolizumab (VED) and ustekinumab (UST) was evaluated as initial UC treatments in patients with biologic-naïve UC.
Methods: This multicenter, randomized control trial was conducted across 20 Japanese medical institutions.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!